<clinical_study>
<study_id>
<org_name>
  BeijingFKP
</org_name>
<org_full_name>
  Beijing Fresenius Kabi Pharmaceutical Co
</org_full_name>
<org_study_id>
  BFP502
</org_study_id>
<nct_id>

</nct_id>
</study_id>
<brief_title>
<textblock>
Hydroxyethylstarch   (130/0.4) for Intravascular Volume Therapy in Liver Transplantation 
</textblock>
</brief_title>
<official_title>
<textblock>
A Multicenter, Randomized, Open-Label, Parallel-Group, Albumin-Controlled Phase IV Study to Evaluate the Efficacy and Safety of Hydroxyethylstarch   (130/0.4) for Intravascular Volume Therapy in Patients Undergoing Liver Transplantation 
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Beijing Fresenius Kabi Pharmaceutical Co
</agency>
</lead_sponsor>
</study_sponsor>
<oversight_info>
<regulatory_authority>
  China: State Food and Drug Administration
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
End-stage liver disease is one of  major causes leading to death. Liver transplantation now becomes  an effective method to recover patients&#8217; liver function, thus save their lives and improve their quality of life. Serious disorders of fluid balance, exist in end stage cirrhosis patients with liver transplantation. Such abnormalities could cause or worsen cardiovascular and pulmonary dysfunction, thus makes the  perioperative management more difficult. 
 
Albumin and blood plasma are conventionally used as plasma volume expanders in clinical practice and has been the   focus of debate for many years   whether albumin should be used for volume replacement in critically ill patients and, furthermore, it is more expensive. 
 



</textblock>
</brief_summary>
<detailed_descr>
<textblock>



 
 



</textblock>
</detailed_descr>
<status_block>
<status>
  Recruiting
</status>
<date>
  2006-03
</date>
</status_block>
<start_date>
<date>
  2005-10
</date>
</start_date>
<end_date>
<date>
  2006-10
</date>
</end_date>
<last_follow_up_date>
<date>
  2006-06
</date>
</last_follow_up_date>
<last_data_entry_date>
<date>
  2006-07
</date>
</last_data_entry_date>
<phase_block>
<phase>
  Phase 4
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Active Control
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<primary_outcome>
  Hemodynamics,
</primary_outcome>
<secondary_outcome>
CTP 
</secondary_outcome>
<secondary_outcome>
MELD 
</secondary_outcome>
<condition>
Liver Transplatation 
</condition>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Hydroxyethyl Starch (130/0.4)
</primary_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:






 
 
  Exclusion Criteria:
- Uncontrolled exo-hepatic malignant carcinomas; 
- Uncontrollable infections (including HIV infection); 
- Need support of artificial liver or kidney, ventilator-dependant, coma or unstable hemodynamic; 
- Patients with a history of hypersensitivity to hydroxyethyl starch or albumin; 
- Urinary output less than 500ml   within 24h   after operation; 
- Patients with intracranial bleeding; 
- Patients with other colloids for treating hypovolemia; 
- Patients with pulmonary edema; 
- Pregnant women or females of childbearing potential,   lactating mothers; 
- Patients who are participating in other drug studies or who receive other investigational drugs within 30 days prior to the present study. 
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<patients>
</patients>
<expected_enrollment>
  200
</expected_enrollment>
<gender>
  Both
</gender>
<minimum_age>
  18 Years
</minimum_age>
<maximum_age>
  65 Years
</maximum_age>
</eligibility>
<investigator>
<role>
  Principal Investigator
</role>
<name>
  Xisheng Leng, MD
</name>
<affiliation>
<agency>
  People&apos;s University of Peking University
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Fengxue Zhu, MD
</name>
<phone>
  13911005275
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<location>
<facility>
<name>
  People&apos;s Hospital of Peking University
</name>
<address>
<city>
  Beijing
</city>
<state>
</state>
<zip>
  100044
</zip>
<country>
  China
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<role>
  Sub-Investigator
</role>
<name>
  Fengxue Zhu, MD
</name>
</contact>
</location>



<initial_release_date>
  2006-03-28
</initial_release_date>
<last_release_date>
2006-03-28 
</last_release_date>
</clinical_study>
